The estimated Net Worth of Markus J. Cappel is at least $7.27 Million dollars as of 4 August 2022. Markus Cappel owns over 7,564 units of ChemoCentryx Inc stock worth over $4,557,339 and over the last 13 years he sold CCXI stock worth over $1,440,792. In addition, he makes $1,271,680 as Chief Business Officer und Treasurer at ChemoCentryx Inc.
Markus has made over 56 trades of the ChemoCentryx Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 7,564 units of CCXI stock worth $379,864 on 4 August 2022.
The largest trade he's ever made was exercising 330,524 units of ChemoCentryx Inc stock on 26 November 2016 worth over $3,754,753. On average, Markus trades about 20,445 units every 52 days since 2012. As of 4 August 2022 he still owns at least 87,658 units of ChemoCentryx Inc stock.
You can see the complete history of Markus Cappel stock trades at the bottom of the page.
Dr. Markus J. Cappel Ph.D. serves as Chief Business Officer, Treasurer of the Company. From March 2003 to February 2007, he served as our Senior Vice President of Corporate and Business Development. From October 2001 to March 2003, Dr. Cappel served as our Vice President of Business Development. Prior to joining us, Dr. Cappel served as Vice President of Business Development at Alkermes, Inc., a biotechnology company, from 1998 to 2001. Prior to this, he served as Director of Business Development with Millennium Pharmaceuticals as well as in various business development roles at Cygnus, Inc., a biotechnology company. Dr. Cappel received his B.S. in pharmacy and his Ph.D. in pharmaceutics from J.W. Goethe University, Frankfurt, Germany, and his M.B.A. from Harvard Business School. Dr. Cappel also completed postdoctoral studies in pharmaceutics at the University of Michigan.
As the Chief Business Officer und Treasurer of ChemoCentryx Inc, the total compensation of Markus Cappel at ChemoCentryx Inc is $1,271,680. There are 2 executives at ChemoCentryx Inc getting paid more, with Thomas Schall having the highest compensation of $3,341,860.
Markus Cappel is 59, he's been the Chief Business Officer und Treasurer of ChemoCentryx Inc since 2007. There are 7 older and 6 younger executives at ChemoCentryx Inc. The oldest executive at ChemoCentryx Inc is Henry McKinnell, 77, who is the Independent Director.
Markus's mailing address filed with the SEC is C/O CHEMOCENTRYX, INC., 835 INDUSTRIAL ROAD, SUITE 600, SAN CARLOS, CA, 94070.
Over the last 13 years, insiders at ChemoCentryx Inc have traded over $355,980,520 worth of ChemoCentryx Inc stock and bought 3,166,975 units worth $19,475,662 . The most active insiders traders include Plc Gsk, Rishi Gupta und (International) Ltd Vifor P.... On average, ChemoCentryx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,175,785. The most recent stock trade was executed by Susan M Kanaya on 16 August 2022, trading 19,898 units of CCXI stock currently worth $216,092.
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
ChemoCentryx Inc executives and other stock owners filed with the SEC include: